Outcome of trabeculectomy with prior intravitreal bevacizumab injection for neovascular glaucoma

Tetsuhiro Kawata, Naoko Yamamoto, Kyoko Matsushita, Tomoko Naito, Hiroshi Ohtsuki, Makiko Takahashi

Research output: Contribution to journalArticle

Abstract

Purpose : To compare the outcome of trabeculectomy for neovascular glaucoma with or without prior in- travitreal injection of bevacizumab. Cases and Method : We reviewed 26 eyes of 24 cases who received trabeculectomy during the past 39 months. Neovascular glaucoma was due to diabetic retinopathy 17 eyes, retinal vein occlusion 6 eyes, and others 3 eyes. Nine eyes received intravitreal bevacizumab one to 14 days before surgery. Results : Final intraocular pressure (IOP) averaged 11.0± 1.4 mmHg in 9 eyes receiving bevacizumb and 9.0± 1.4 mmHg in the other 17 eyes. When final IOP over 15 mmHg or additional treatment glaucoma was defined as death, rate of survival was 77.7% in 9 eyes receiving bevacizumab and 60.0% in the other 17 eyes 12 months after surgery. There was no significant difference between the two groups. Conclusion : Intravitreal injection of bevacizumab may decrease late complications of trabeculectomy and may induce early IOP control.

Original languageEnglish
Pages (from-to)1457-1460
Number of pages4
JournalJapanese Journal of Clinical Ophthalmology
Volume63
Issue number9
Publication statusPublished - Sep 2009
Externally publishedYes

Fingerprint

Neovascular Glaucoma
Intravitreal Injections
Trabeculectomy
Intraocular Pressure
Bevacizumab
Retinal Vein Occlusion
Diabetic Retinopathy
Ambulatory Surgical Procedures
Glaucoma

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Kawata, T., Yamamoto, N., Matsushita, K., Naito, T., Ohtsuki, H., & Takahashi, M. (2009). Outcome of trabeculectomy with prior intravitreal bevacizumab injection for neovascular glaucoma. Japanese Journal of Clinical Ophthalmology, 63(9), 1457-1460.

Outcome of trabeculectomy with prior intravitreal bevacizumab injection for neovascular glaucoma. / Kawata, Tetsuhiro; Yamamoto, Naoko; Matsushita, Kyoko; Naito, Tomoko; Ohtsuki, Hiroshi; Takahashi, Makiko.

In: Japanese Journal of Clinical Ophthalmology, Vol. 63, No. 9, 09.2009, p. 1457-1460.

Research output: Contribution to journalArticle

Kawata, T, Yamamoto, N, Matsushita, K, Naito, T, Ohtsuki, H & Takahashi, M 2009, 'Outcome of trabeculectomy with prior intravitreal bevacizumab injection for neovascular glaucoma', Japanese Journal of Clinical Ophthalmology, vol. 63, no. 9, pp. 1457-1460.
Kawata T, Yamamoto N, Matsushita K, Naito T, Ohtsuki H, Takahashi M. Outcome of trabeculectomy with prior intravitreal bevacizumab injection for neovascular glaucoma. Japanese Journal of Clinical Ophthalmology. 2009 Sep;63(9):1457-1460.
Kawata, Tetsuhiro ; Yamamoto, Naoko ; Matsushita, Kyoko ; Naito, Tomoko ; Ohtsuki, Hiroshi ; Takahashi, Makiko. / Outcome of trabeculectomy with prior intravitreal bevacizumab injection for neovascular glaucoma. In: Japanese Journal of Clinical Ophthalmology. 2009 ; Vol. 63, No. 9. pp. 1457-1460.
@article{cee19259e0b44af78b892cc09d09f06b,
title = "Outcome of trabeculectomy with prior intravitreal bevacizumab injection for neovascular glaucoma",
abstract = "Purpose : To compare the outcome of trabeculectomy for neovascular glaucoma with or without prior in- travitreal injection of bevacizumab. Cases and Method : We reviewed 26 eyes of 24 cases who received trabeculectomy during the past 39 months. Neovascular glaucoma was due to diabetic retinopathy 17 eyes, retinal vein occlusion 6 eyes, and others 3 eyes. Nine eyes received intravitreal bevacizumab one to 14 days before surgery. Results : Final intraocular pressure (IOP) averaged 11.0± 1.4 mmHg in 9 eyes receiving bevacizumb and 9.0± 1.4 mmHg in the other 17 eyes. When final IOP over 15 mmHg or additional treatment glaucoma was defined as death, rate of survival was 77.7{\%} in 9 eyes receiving bevacizumab and 60.0{\%} in the other 17 eyes 12 months after surgery. There was no significant difference between the two groups. Conclusion : Intravitreal injection of bevacizumab may decrease late complications of trabeculectomy and may induce early IOP control.",
author = "Tetsuhiro Kawata and Naoko Yamamoto and Kyoko Matsushita and Tomoko Naito and Hiroshi Ohtsuki and Makiko Takahashi",
year = "2009",
month = "9",
language = "English",
volume = "63",
pages = "1457--1460",
journal = "Japanese Journal of Clinical Ophthalmology",
issn = "0370-5579",
publisher = "Igaku-Shoin Ltd",
number = "9",

}

TY - JOUR

T1 - Outcome of trabeculectomy with prior intravitreal bevacizumab injection for neovascular glaucoma

AU - Kawata, Tetsuhiro

AU - Yamamoto, Naoko

AU - Matsushita, Kyoko

AU - Naito, Tomoko

AU - Ohtsuki, Hiroshi

AU - Takahashi, Makiko

PY - 2009/9

Y1 - 2009/9

N2 - Purpose : To compare the outcome of trabeculectomy for neovascular glaucoma with or without prior in- travitreal injection of bevacizumab. Cases and Method : We reviewed 26 eyes of 24 cases who received trabeculectomy during the past 39 months. Neovascular glaucoma was due to diabetic retinopathy 17 eyes, retinal vein occlusion 6 eyes, and others 3 eyes. Nine eyes received intravitreal bevacizumab one to 14 days before surgery. Results : Final intraocular pressure (IOP) averaged 11.0± 1.4 mmHg in 9 eyes receiving bevacizumb and 9.0± 1.4 mmHg in the other 17 eyes. When final IOP over 15 mmHg or additional treatment glaucoma was defined as death, rate of survival was 77.7% in 9 eyes receiving bevacizumab and 60.0% in the other 17 eyes 12 months after surgery. There was no significant difference between the two groups. Conclusion : Intravitreal injection of bevacizumab may decrease late complications of trabeculectomy and may induce early IOP control.

AB - Purpose : To compare the outcome of trabeculectomy for neovascular glaucoma with or without prior in- travitreal injection of bevacizumab. Cases and Method : We reviewed 26 eyes of 24 cases who received trabeculectomy during the past 39 months. Neovascular glaucoma was due to diabetic retinopathy 17 eyes, retinal vein occlusion 6 eyes, and others 3 eyes. Nine eyes received intravitreal bevacizumab one to 14 days before surgery. Results : Final intraocular pressure (IOP) averaged 11.0± 1.4 mmHg in 9 eyes receiving bevacizumb and 9.0± 1.4 mmHg in the other 17 eyes. When final IOP over 15 mmHg or additional treatment glaucoma was defined as death, rate of survival was 77.7% in 9 eyes receiving bevacizumab and 60.0% in the other 17 eyes 12 months after surgery. There was no significant difference between the two groups. Conclusion : Intravitreal injection of bevacizumab may decrease late complications of trabeculectomy and may induce early IOP control.

UR - http://www.scopus.com/inward/record.url?scp=70350337763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350337763&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:70350337763

VL - 63

SP - 1457

EP - 1460

JO - Japanese Journal of Clinical Ophthalmology

JF - Japanese Journal of Clinical Ophthalmology

SN - 0370-5579

IS - 9

ER -